

Akebia Therapeutics to Report Fourth Quarter and Full-Year 2022 Financial Results and Discuss Recent Business Highlights

March 2, 2023

Akebia to Host Conference Call

CAMBRIDGE, Mass., March 2, 2023 /PRNewswire/ -- <u>Akebia Therapeutics. Inc.</u> (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced plans to release its financial results for the fourth quarter and full-year ended December 30, 2022 on Thursday, March 9 prior to the open of financial markets.

Akebia will host a conference call on Thursday, March 9 at 8:30 a.m. ET to discuss its financial results and recent business highlights. To access the call by phone, please click on this <u>Registration Link</u> and you will be provided with dial in details. To avoid delays, we encourage dialing into the conference call fifteen minutes ahead of the scheduled start time.

A live webcast of the conference call will be available via the Investors section of Akebia's website at: <u>https://ir.akebia.com/</u>. An online archive of the webcast can be accessed via the Investors section of Akebia's website at <u>http://ir.akebia.com</u>.

About Akebia Therapeutics

Akebia Therapeutics, Inc. is a fully integrated biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease. Akebia was founded in 2007 and is headquartered in Cambridge, Massachusetts. For more information, please visit our website at www.akebia.com, which does not form a part of this release.

Akebia Therapeutics Contact

Mercedes Carrasco mcarrasco@akebia.com

C View original content to download multimedia: <u>https://www.prnewswire.com/news-releases/akebia-therapeutics-to-report-fourth-quarter-and-full-year-2022-financial-results-and-discuss-recent-business-highlights-301759965.html</u>

SOURCE Akebia Therapeutics